- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03934372
Segurança e Eficácia de Ponatinibe para Tratamento de Leucemias Pediátricas Recorrentes ou Refratárias, Linfomas ou Tumores Sólidos
Um estudo aberto, de braço único, fase 1/2 avaliando a segurança e a eficácia do ponatinibe para o tratamento de leucemias, linfomas ou tumores sólidos recorrentes ou refratários em participantes pediátricos
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Incyte Corporation Call Center (ex-US)
- Número de telefone: +800 00027423
- E-mail: globalmedinfo@incyte.com
Locais de estudo
-
-
-
Ghent, Bélgica, 09000
- Recrutamento
- Ghent University Hospital
-
-
-
-
-
Barcelona, Espanha, 08035
- Recrutamento
- Hospital General Universitario Vall D Hebron
-
Barcelona, Espanha, 08035
- Recrutamento
- Hospital Sant Joan de Deu de Manresa
-
Madrid, Espanha, 28009
- Recrutamento
- Hospital Infantil Unversitario Nino Jesus
-
Valencia, Espanha, 46026
- Recrutamento
- Hospital Universitari I Politecnic La Fe
-
-
-
-
-
Paris, França, 75019
- Recrutamento
- Hopital Robert Debre
-
Paris, França, 75571
- Recrutamento
- Armand Trousseau Hospital
-
Poitiers, França, 86021
- Recrutamento
- Centre Hospitalier Universitaire de Poitiers
-
Rennes, França, 35203
- Concluído
- Chu de Rennes - Hospital Sud
-
-
-
-
-
Utrecht, Holanda, 03584
- Recrutamento
- Princess Maxima Center For Pediatric Oncology
-
-
-
-
-
Bologna, Itália, 40138
- Recrutamento
- Aou Policlinico S. Orsola-Malpighi
-
Brescia, Itália, 25123
- Recrutamento
- Asst Degli Spedali Civili Di Brescia
-
Genova, Itália, 16147
- Recrutamento
- Ospedale Pediatrico G. Gaslini
-
Milan, Itália, 20133
- Recrutamento
- Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano
-
Monza, Itália, 20900
- Recrutamento
- University of Milano Bicocca
-
Naples, Itália, 80123
- Recrutamento
- Aorn Santobono Pausilipon
-
Pavia, Itália, 27100
- Recrutamento
- Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
-
Rome, Itália, 00165
- Recrutamento
- Ospedale Pediatrico Bambino Gesu Irccs
-
Torino, Itália, 10126
- Recrutamento
- A.O.U Citta Della Salute E Della Scienza Di Torino Presidio Ospedaliero Infantile Regina Margherita
-
-
-
-
-
Glasgow, Reino Unido, G514TF
- Recrutamento
- Royal Hospital For Sick Children Yorkhill Glasgow
-
Liverpool, Reino Unido, L12 2AP
- Recrutamento
- Alder Hey Childrens Nhs Foundation Trust
-
Sutton, Reino Unido, SM2 5PT
- Recrutamento
- The Royal Marsden Nhs Foundation Trust - Sutton
-
-
-
-
-
Stockholm, Suécia, 14141
- Recrutamento
- Karolinska University Hospital Solna
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Histologically or cytologically confirmed diagnosis of the following malignancies:
- Phase 1: CP-CML, BP-CML, AP-CML ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of the CNS, for which standard therapy is not available or is not indicated.
- Phase 2, Group A with CP-CML: CP-CML at the time of study entry and must be resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy or be in "warning" response status or have the T315I kinase domain mutation.
Must have 1 bone marrow aspirate with documentation of BCR-ABL translocation by conventional cytogenetics, metaphase FISH, or q-PCR performed within 42 days before the first dose of ponatinib.
- Phase 2, Group B with other leukemias or solid tumors: ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of the CNS, with mutations of RET, FLT3, KIT, FGFR, PDGFR, TIE2, VEGFR, or any other mutations where ponatinib may have biological activity (eg, EPH receptors and SRC families of kinases) as assessed on fresh or archived tumor tissue.
Participants with solid tumors or with lymphoma must have measurable disease by CT or MRI based on RECIST v1.1 or the Lugano lymphoma guidelines as determined by site radiology.
Prior therapies as follows:
- Phase 1: Participants with CML who are resistant to or intolerant of (as defined Appendix F) to at least 1 prior BCR-ABL-targeted TKI therapy.
Participants with ALL who have progressed on or after all available or indicated therapies, which may have included 1 prior BCR-ABL-targeted TKI therapy.
Participants with AML or other leukemias who have progressed on or after at least 1 prior induction attempt (for France only) or for whom no effective standard therapy is available or indicated (other countries).
Participants with solid tumors (including tumors of the CNS) or lymphomas who have progressed despite standard therapy or for whom no effective standard therapy is available or indicated.
- Phase 2, Group A with CP-CML: Participants who are resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI therapy.
- Phase 2, Group B with other leukemias or solid tumors: Participants with ALL who have progressed on or after all available or indicated therapies, which must have included 1 prior BCR-ABL-targeted TKI therapy.
Participants with AML or other leukemias who have progressed on or after at least 1 prior induction attempt (for France only) or for whom no effective standard therapy is available or indicated (other countries).
Participants with solid tumors (including tumors of the CNS) or lymphomas who progressed despite standard therapy or for whom no effective standard therapy is available or indicated.
- Karnofsky performance status ≥ 40% for participants ≥ 16 years old or Lansky Play Scale ≥ 40% for pediatric participants < 16 years old.
- Participants must have recovered to < Grade 2 per the NCI CTCAE v5.0 or to baseline from any non-hematologic toxicities (except alopecia) due to previous therapy.
- Willingness to avoid pregnancy or fathering children.
Exclusion Criteria:
Prior therapies:
- Participants with BP-CML, ALL, or AML who have received any of the following: Corticosteroids or hydroxyurea within 24 hours before the first dose of ponatinib.
Vincristine within 7 days before the first dose of ponatinib. Other chemotherapy (excluding intrathecal chemotherapy) within 14 days before the first dose of ponatinib.
- Participants (except the BP-CML, ALL, and AML participants described above) who: Have had cytotoxic chemotherapy within 21 days (or 42 days for nitrosoureas or mitomycin C) before the first dose of ponatinib.
Prior radiation therapy or radio-isotope therapy within 6 weeks before the first dose of ponatinib except local radiotherapy for palliative indication within 14 days before the first dose of ponatinib.
Autologous or allogeneic stem cell transplant < 3 months before the first dose of ponatinib.
Major surgery within 14 days before the first dose of ponatinib. Inadequate recovery and/or complications from a major surgery before starting therapy.
Prior treatment with any of the following:
- Immunosuppressive therapy (including post stem cell transplant regimens) within 14 days before the first dose of ponatinib.
- Any targeted cancer therapy (including TKIs) within 7 days before the first dose of ponatinib.
- Any other investigational anticancer agents within 30 days or 5 half-lives, whichever is longer, before randomization.
- Any monoclonal antibody-directed anticancer therapy within 5 half-lives of the first dose of ponatinib.
- Any chimeric antigen receptor therapy within 28 days before the first dose of ponatinib
- Ponatinib
- Protocol-defined lab Values
- Significant concurrent, uncontrolled medical condition, including but not limited to the following:
- Pancreatic: clinical, radiological, or laboratory evidence of pancreatitis.
- Cardiac:
- SF < 27% by ECHO, OR EF < 50% by MUGA.
- Abnormal QTcF on screening ECG, defined as QTcF of ≥ 450 ms.
- Clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute MI within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV CHF (see Appendix P), and arrhythmia requiring therapy unless approved by the medical monitor/sponsor.
- Uncontrolled hypertension.
- Currently taking drug(s) that are known to have a risk of causing prolonged QTc or TdP unless the drug(s) can be changed to acceptable alternatives (ie, an alternate class of agents that do not affect the cardiac conduction system), or the participant can safely discontinue the drug(s).
- Cerebral:
- Participants with solid tumors with intracranial metastasis OR participants with active CNS leukemia (ie, CNS-2 status [< 5/μL WBCs and cytospin positive for blasts, or ≥ 5 /μL WBCs but negative by Steinherz/Bleyer algorithm (equation used for traumatic lumbar punctures), disseminated leptomeningeal disease, or CNS chloroma.
- Pre-existing significant CNS pathology including history of severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination/movement disorder, or autoimmune disease with CNS involvement.
- History of cerebrovascular ischemia/hemorrhage with residual deficits.
- Note: Participants with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved clinically according to Inclusion Criterion 6.
- Uncontrolled seizure disorder.
- Coagulation:
- Significant bleeding disorder or thrombophilia unrelated to the underlying malignancy indication for study participation.
- Gastrointestinal:
- Gastrointestinal disorders, such as malabsorption syndrome or any other illness that could affect oral absorption.
- Genetic:
- Participants with DNA fragility syndromes, such as Fanconi anemia and Bloom syndrome.
- Participants with Down syndrome.
- Participants with any active ≥ Grade 2 graft versus host disease.
- Chronic or current active uncontrolled infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
- Active HBV or HCV infection that requires treatment or at risk for HBV reactivation. Hepatitis B virus DNA and HCV RNA must be undetectable upon testing. At risk for HBV reactivation is defined as hepatitis B surface antigen positive or anti-hepatitis B core antibody positive.
- Known HIV infection.
- Current use of prohibited medication (see Section 6.7.2).
- Known hypersensitivity or severe reaction to ponatinib or excipients of ponatinib.
- Receipt of live (including attenuated) vaccines or anticipation of need for such vaccines during the study.
- Inability or unlikeliness to comply with the dose schedule and study evaluations, in the opinion of the investigator.
- Females who are pregnant or lactating.
- Other exclusions may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Ponatinib
Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose. |
Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fase 2: Eficácia do ponatinibe avaliada por resposta completa (CR) em participantes com leucemias diferentes das leucemias positivas para BCR-ABL para determinar a eficácia do ponatinibe
Prazo: 6 meses
|
6 meses
|
|
|
Phase 1: Number of dose-limiting toxicities
Prazo: 28 days
|
Defined as the occurrence of any protocol-defined toxicities occurring after dosing and up to and including Day 28, except those toxicities with a clear alternative explanation. |
28 days
|
|
Phase 2: Efficacy of ponatinib assessed by major cytogenetic response (MCyR) in participants with chronic-phase chronic myeloid leukemia (CP-CML)
Prazo: 12 months
|
Defined as complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR) as assessed by conventional cytogenetics or fluorescence in situ hybridization (FISH). |
12 months
|
|
Phase 2: Efficacy of ponatinib assessed by major hematologic response (MaHR) or major molecular response (MMR) in participants with BCR-ABL-positive leukemias
Prazo: 3 months
|
Assessed by polymerase chain reaction (PCR). |
3 months
|
|
Phase 2: Efficacy of ponatinib assessed by incomplete complete response (iCR) in participants with leukemias other than BCR-ABL-positive leukemias
Prazo: 6 months
|
Assessed by conventional cytogenetics, FISH, or PCR. |
6 months
|
|
Phase 2: Efficacy of ponatinib assessed by CR in participants with lymphoma
Prazo: 6 months
|
According to Lugano criteria based on computed tomography (CT) or magnetic resonance imaging (MRI) (or positron emission tomography [PET]). |
6 months
|
|
Phase 2: Efficacy of ponatinib assessed by overall response rate in participants with solid tumors
Prazo: 6 months
|
Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for central nervous system (CNS) tumors or Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for other solid tumors based on CT or MRI (or PET). |
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fase 1: Número de eventos adversos emergentes do tratamento
Prazo: 6 meses
|
6 meses
|
|
|
Fase 1 e Fase 2: Resposta hematológica completa (CHR) em participantes com CP-CML
Prazo: 6 meses
|
6 meses
|
|
|
Fase 1 e Fase 2: CCyR em participantes com CP-CML
Prazo: 12 meses
|
12 meses
|
|
|
Fase 1 e Fase 2: MMR em participantes com CP-CML
Prazo: 12 meses
|
12 meses
|
|
|
Fase 1: CR em participantes com leucemias que não sejam leucemia BCR-ABL positiva ou CP-CML.
Prazo: 6 meses
|
6 meses
|
|
|
Fase 2: Atividade anticancerígena de ponatinibe avaliada por MaHR ou MMR em participantes com leucemias positivas para BCR-ABL (AP-CML, BP-CML ou Ph+ALL)
Prazo: 3 meses
|
3 meses
|
|
|
Fase 2: Atividade anticancerígena de ponatinibe avaliada por CR em participantes com leucemias que não sejam leucemias BCR-ABL positivas
Prazo: 6 meses
|
6 meses
|
|
|
Fase 2: Número de eventos adversos emergentes do tratamento
Prazo: 6 meses
|
6 meses
|
|
|
Fase 2: Liberação da formulação pediátrica de ponatinibe
Prazo: 6 meses
|
6 meses
|
|
|
Fase 2: Volume de distribuição da formulação pediátrica de ponatinibe
Prazo: 6 meses
|
6 meses
|
|
|
Fase 2: AUC da formulação pediátrica de ponatinibe
Prazo: 6 meses
|
6 meses
|
|
|
Phase 1: Tmax of ponatinib
Prazo: 6 months
|
Time to maximum concentration. |
6 months
|
|
Phase 1: AUCss,0-24 of ponatinib
Prazo: 6 months
|
Area under the steady-state plasma or serum concentration-time curve from Hour 0 to 24. |
6 months
|
|
Phase 1: t½ of ponatinib
Prazo: 6 months
|
Apparent terminal-phase disposition half-life. |
6 months
|
|
Phase 1: CLss/F of ponatinib
Prazo: 6 months
|
Apparent oral dose clearance at steady state. |
6 months
|
|
Phase 1: Vz/F of ponatinib
Prazo: 6 months
|
Apparent oral dose volume of distribution. |
6 months
|
|
Phase 1: MCyR in participants with BCR-ABL-positive leukemias
Prazo: 3 months
|
Defined as CCyR or PCyR as assessed by conventional cytogenetics or FISH. |
3 months
|
|
Phase 1: MMR in participants with BCR-ABL-positive leukemias
Prazo: 3 months
|
Assessed by quantitative PCR (q-PCR). |
3 months
|
|
Phase 1 and Phase 2: Time to response (TTR) in participants with CP-CML
Prazo: 6 months
|
Defined as the interval from the date of the first dose of study treatment to first response. |
6 months
|
|
Phase 1 and Phase 2: Duration of response (DOR) in participants with CP-CML
Prazo: 6 months
|
Defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met. |
6 months
|
|
Phase 1 and Phase 2: Progression-free survival (PFS) in participants with CP-CML
Prazo: 6 months
|
Defined as the interval from the date of the first dose of study treatment until the date of progression of disease or the date of death from any cause, whichever is earlier. |
6 months
|
|
Phase 1 and Phase 2: Overall survival (OS) in participants with CP-CML
Prazo: 6 months
|
Defined as the interval from the date of the first dose of study treatment until death from any cause. |
6 months
|
|
Phase 1: CRi in participants with leukemias other than BCR-ABL-positive leukemia or CP-CML
Prazo: 6 months
|
Assessed by conventional cytogenetics, FISH, or q-PCR. |
6 months
|
|
Phase 1: CR in participants with lymphoma
Prazo: 6 months
|
According to Lugano criteria based on CT or MRI (or PET). |
6 months
|
|
Phase 1: Overall response rate in participants with solid tumors
Prazo: 6 months
|
Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for CNS tumors or RECIST v1.1 for other solid tumors based on CT or MRI (or PET). |
6 months
|
|
Phase 2: Anticancer activity of ponatinib assessed by CRi in participants with leukemias other than BCR-ABL-positive leukemias.
Prazo: 6 months
|
Assessed by conventional cytogenetics, FISH, or PCR. |
6 months
|
|
Phase 2: Anticancer activity of ponatinib assessed by CR in participants with lymphoma
Prazo: 6 months
|
According to Lugano criteria based on CT or MRI (or PET). |
6 months
|
|
Phase 2: Anticancer activity of ponatinib assessed by overall response rate in participants with solid tumors
Prazo: 6 months
|
Defined as the percentage of participants having CR or PR, as determined by investigator assessment of radiographic disease per tumors per RANO for CNS tumors or RECIST v1.1 for other solid tumors based on CT or MRI (or PET). |
6 months
|
|
Phase 2: OS in participants with solid tumors
Prazo: 6 months
|
Defined as the interval from the date of the first dose of study treatment until death from any cause. |
6 months
|
|
Phase 2: DOR in participants with solid tumors
Prazo: 6 months
|
Defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met. |
6 months
|
|
Phase 2: PFS in participants with solid tumors
Prazo: 6 months
|
Defined as the interval from the date of the first dose of study treatment until the date of progression of disease or the date of death from any cause, whichever is earlier. |
6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Mohammed-El-Amine Bensmaine, MD, Incyte Biosciences International Sàrl
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias
- Doença crônica
- Atributos da doença
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Processos Neoplásicos
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Leucemia Mieloide
- Doenças da Medula Óssea
- Leucemia Linfóide
- Distúrbios mieloproliferativos
- Leucemia Mielóide, Crônica, BCR-ABL Positivo
- Transformação Celular Neoplásica
- Carcinogênese
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Leucemia
- Leucemia Mieloide Aguda
- Linfoma
- Leucemia-Linfoma Linfoblástico de Células Precursoras
- Crise Explosiva
- Leucemia Mielóide de Fase Crônica
- Leucemia Mieloide Fase Acelerada
- Ponatinibe
Outros números de identificação do estudo
- INCB 84344-102
- 2018 (Concessão/Contrato do NIH dos EUA)
- 2018-004878-99 (Número EudraCT)
- 2023-509699-41-00 (Identificador de registro: EU CT Number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .